KR20190136284A - 안정한 아자시티딘-함유 약제학적 조성물의 제조방법 - Google Patents

안정한 아자시티딘-함유 약제학적 조성물의 제조방법 Download PDF

Info

Publication number
KR20190136284A
KR20190136284A KR1020180061784A KR20180061784A KR20190136284A KR 20190136284 A KR20190136284 A KR 20190136284A KR 1020180061784 A KR1020180061784 A KR 1020180061784A KR 20180061784 A KR20180061784 A KR 20180061784A KR 20190136284 A KR20190136284 A KR 20190136284A
Authority
KR
South Korea
Prior art keywords
azacytidine
preparation
temperature
acetonitrile
solution
Prior art date
Application number
KR1020180061784A
Other languages
English (en)
Korean (ko)
Inventor
조중웅
김경해
이일웅
Original Assignee
주식회사 삼양바이오팜
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 삼양바이오팜 filed Critical 주식회사 삼양바이오팜
Priority to KR1020180061784A priority Critical patent/KR20190136284A/ko
Priority to JP2020566917A priority patent/JP7148642B2/ja
Priority to PCT/KR2019/006415 priority patent/WO2019231225A1/ko
Publication of KR20190136284A publication Critical patent/KR20190136284A/ko
Priority to KR1020210079877A priority patent/KR20210078462A/ko
Priority to JP2022152920A priority patent/JP2022185009A/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020180061784A 2018-05-30 2018-05-30 안정한 아자시티딘-함유 약제학적 조성물의 제조방법 KR20190136284A (ko)

Priority Applications (5)

Application Number Priority Date Filing Date Title
KR1020180061784A KR20190136284A (ko) 2018-05-30 2018-05-30 안정한 아자시티딘-함유 약제학적 조성물의 제조방법
JP2020566917A JP7148642B2 (ja) 2018-05-30 2019-05-29 安定したアザシチジン含有医薬組成物の製造方法
PCT/KR2019/006415 WO2019231225A1 (ko) 2018-05-30 2019-05-29 안정한 아자시티딘-함유 약제학적 조성물의 제조방법
KR1020210079877A KR20210078462A (ko) 2018-05-30 2021-06-21 안정한 아자시티딘-함유 약제학적 조성물의 제조방법
JP2022152920A JP2022185009A (ja) 2018-05-30 2022-09-26 安定したアザシチジン含有医薬組成物の製造方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020180061784A KR20190136284A (ko) 2018-05-30 2018-05-30 안정한 아자시티딘-함유 약제학적 조성물의 제조방법

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020210079877A Division KR20210078462A (ko) 2018-05-30 2021-06-21 안정한 아자시티딘-함유 약제학적 조성물의 제조방법

Publications (1)

Publication Number Publication Date
KR20190136284A true KR20190136284A (ko) 2019-12-10

Family

ID=68698347

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020180061784A KR20190136284A (ko) 2018-05-30 2018-05-30 안정한 아자시티딘-함유 약제학적 조성물의 제조방법
KR1020210079877A KR20210078462A (ko) 2018-05-30 2021-06-21 안정한 아자시티딘-함유 약제학적 조성물의 제조방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020210079877A KR20210078462A (ko) 2018-05-30 2021-06-21 안정한 아자시티딘-함유 약제학적 조성물의 제조방법

Country Status (3)

Country Link
JP (2) JP7148642B2 (ja)
KR (2) KR20190136284A (ja)
WO (1) WO2019231225A1 (ja)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110042247A1 (en) 2009-06-25 2011-02-24 Chandrasekhar Kocherlakota Formulations of azacitidine and its derivatives
US9951098B2 (en) 2011-03-31 2018-04-24 Pharmion Llc Synthesis of 5-azacytidine
KR101286802B1 (ko) * 2011-07-15 2013-07-23 보령제약 주식회사 아자시티딘의 전―동결건조 제제, 아자시티딘의 동결건조 제제 및 이의 제조방법
WO2013117969A1 (en) * 2012-02-06 2013-08-15 Fresenius Kabi Oncology Ltd. Process for preparing stable pharmaceutical compositions of compounds susceptible to hydrolysis
WO2014076616A2 (en) 2012-11-19 2014-05-22 Shilpa Medicare Limited Formulations of 5-azacytidine

Also Published As

Publication number Publication date
WO2019231225A1 (ko) 2019-12-05
JP2022500350A (ja) 2022-01-04
JP7148642B2 (ja) 2022-10-05
KR20210078462A (ko) 2021-06-28
JP2022185009A (ja) 2022-12-13

Similar Documents

Publication Publication Date Title
TWI472515B (zh) 苯達莫斯汀鹽酸鹽（ｂｅｎｄａｍｕｓｔｉｎｅ ｈｙｄｒｏｃｈｌｏｒｉｄｅ）之新穎固體型式
KR101188691B1 (ko) 엑티나시딘 및 디사카라이드를 포함하는 제제
US9872873B2 (en) Process for preparing stable pharmaceutical compositions of compounds susceptible to hydrolysis
JP6869941B2 (ja) ある含有量のマイトマイシンｃを有する凍結乾燥医薬組成物を製造する方法
WO2006024945A1 (en) Pharmaceutical compositions comprising a cdk inhibitor
CA2529598C (en) Stable freeze-dried pharmaceutical formulation of tetrodotoxin
BR112015005400B1 (pt) Formulação de daptomicina liofilizada, formulação de daptomicina reconstituída, método para tratar um biofilme e método para preparar uma formulação de daptomicina liofilizada
EP2958554B1 (en) Stable compositions of bendamustine
EA006388B1 (ru) Сложные эфиры апорфина и их применение в терапии
JP4142149B2 (ja) バンコマイシンの凍結乾燥製剤
JP2022185009A (ja) 安定したアザシチジン含有医薬組成物の製造方法
JP6091597B2 (ja) シクロペプチド系化合物の水和物およびその製造方法と使用
EP2922530B1 (en) Caspofungin acetate formulations
CN111278430A (zh) 库潘尼西制剂
WO2015025000A1 (en) Pharmaceutical compositions comprising bortezomib
WO2014102731A1 (en) Novel pharmaceutical compositions of romidepsin
CA2894935A1 (en) Novel crystalline forms of ceftaroline fosamil
RU2554939C1 (ru) Противоопухолевый антрафурандион и фармацевтические композиции на его основе
WO2014076616A2 (en) Formulations of 5-azacytidine
US9765108B2 (en) Formulation of 5-azacytidine
WO2023237480A1 (en) Stable pharmaceutical compositions comprising 5,10-methylene-(6r)-tetrahydrofolic acid and nacl
KR101891728B1 (ko) 펩타이드 붕소산 화합물을 함유하는 안정화 약학 제제
US20020099043A1 (en) Freeze-dried product and method for preparing the same
DK2436386T3 (en) A stabilized and lyophilized formulation of the anthracycline compounds
EP3035914A1 (en) Pharmaceutical compositions comprising bortezomib

Legal Events

Date Code Title Description
A201 Request for examination
AMND Amendment
E902 Notification of reason for refusal
AMND Amendment
E601 Decision to refuse application
AMND Amendment
X601 Decision of rejection after re-examination
N231 Notification of change of applicant
A107 Divisional application of patent